Urinary Method Detects Toxin Exposure from Harmful Algal Blooms
By LabMedica International staff writers Posted on 29 Jan 2020 |

Image: The Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Photo courtesy of Thermo Fisher Scientific).
During harmful algal blooms (HABs), species of cyanobacteria release toxic peptides, including microcystins and nodularin into waterways, impacting wildlife and humans living in these marine environments.
Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.
A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).
The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).
The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.
The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.
Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters
Human exposure comes from ingestion, direct skin contact, or inhalation and can lead to a variety of symptoms ranging from gastroenteritis, nausea, allergic reactions and skin rashes to hepatic injury and hemorrhage in more severe cases. Microcystins also have been linked to tumor progression and are harmful to renal, immune and reproductive systems.
A group of scientists led by the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA) tested a newly developed immunocapture protein phosphatase inhibition assay (IC-PPIA) method for detection of microcystins and nodularin in human urine. This method uses a commercially available antibody to specifically isolate microcystins and nodularine from human urine prior to measurement. Urines from the Florida residents were self-collected by participants into sterile collection cups and stored at −80 °C until shipment to the Florida Atlantic University laboratory (Ft. Pierce, FL, USA).
The team used the Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) to measure peak areas from the samples. The highly toxic MC congener microcystin-LR was resolved on an Agilent 1290 liquid chromatograph (Agilent Technologies, Santa Clara, CA, USA) using an Acquity UPLC BEH C18 column (Waters, Milford, MA, USA). A Protein Phosphatase Inhibition Assay was performed and the absorbance was read at 405 nm on a Powerwave HT microplate spectrophotometer (BioTek, Winooski, VT, USA).
The scientists demonstrated that the IC-PPIA method developed by the CDC was able to detect low-dose human exposures to microcystins by analysis of urine from three of the 86 urine specimens analyzed by this new method, which yielded positive results with concentrations of 0.055, 0.089 and 0.052 ng/mL MC-LR equivalents. These findings are the first to report microcystin concentrations directly from exposed residents impacted by cyanobacteria in Florida.
The authors concluded that they had described the development and application of an IC-PPIA for detection of nearly all microcystins (MCs) and nodularin (NOD) in human urine. Ten-fold sample concentration in this method makes it sensitive enough to detect even low-level human inhalation exposures to MCs and NOD. This method could complement water monitoring programs by identifying human exposures to MCs and NOD at the time of HABs and may assist in elucidating health effects associated with these toxins in the future. The study was published on December 19, 2019 in the journal Toxins.
Related Links:
Centers for Disease Control and Prevention
Florida Atlantic University
Thermo Fisher Scientific
Agilent Technologies
BioTek
Waters
Latest Clinical Chem. News
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
Channels
Molecular Diagnostics
view channel
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read more
Liquid Biopsy Assay Detects Recurrence in CRC Patients Prior to Imaging
The detection of circulating tumor DNA (ctDNA) after treatment is a strong indicator of recurrence in colorectal cancer (CRC), but it often goes undetected due to the low traces of ctDNA present in the blood.... Read more
Ultra Fast Synovial Fluid Test Diagnoses Osteoarthritis and Rheumatoid Arthritis In 10 Minutes
Studies indicate that more than 50% of individuals aged 65 and older experience symptoms of osteoarthritis, while rheumatoid arthritis is a serious chronic condition affecting approximately 1 in 100 people... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read more
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read more
AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
Pediatric sarcomas are rare and diverse tumors that can develop in various types of soft tissue, such as muscle, tendons, fat, blood or lymphatic vessels, nerves, or the tissue surrounding joints.... Read more
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more